133 related articles for article (PubMed ID: 7823604)
1. Nuclear texture: can it be used as a surrogate endpoint biomarker?
Palcic B
J Cell Biochem Suppl; 1994; 19():40-6. PubMed ID: 7823604
[TBL] [Abstract][Full Text] [Related]
2. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
Boone CW; Kelloff GJ
J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of morphological nuclear parameters and DNA ploidy pattern in precancerous lesions of the uterine cervix.
Kashyap V; Luthra UK
Indian J Pathol Microbiol; 1995 Apr; 38(2):193-7. PubMed ID: 8919109
[TBL] [Abstract][Full Text] [Related]
4. Endpoint markers for clinical trials of chemopreventive agents derived from the properties of epithelial precancer (intraepithelial neoplasia) measured by computer-assisted image analysis.
Boone CW; Kelloff GJ
Cancer Surv; 1998; 32():133-47. PubMed ID: 10489626
[TBL] [Abstract][Full Text] [Related]
5. Nuclear texture measurements in image cytometry.
Doudkine A; Macaulay C; Poulin N; Palcic B
Pathologica; 1995 Jun; 87(3):286-99. PubMed ID: 8570289
[TBL] [Abstract][Full Text] [Related]
6. Nuclear grading and flow cytometric DNA pattern in fine-needle aspirates of primary breast cancer.
Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Manotti L; Pilato FP; Mazzini G; Cocconi G
Diagn Cytopathol; 1996 Aug; 15(2):116-20. PubMed ID: 8872432
[TBL] [Abstract][Full Text] [Related]
7. Influence of different cell extraction methods on cytometric features.
Thunnissen FB; Perdaen H; Forrest J
Cytometry; 1992; 13(5):485-9. PubMed ID: 1633727
[TBL] [Abstract][Full Text] [Related]
8. G-actin as a risk factor and modulatable endpoint for cancer chemoprevention trials.
Hemstreet GP; Rao J; Hurst RE; Bonner RB; Waliszewski P; Grossman HB; Liebert M; Bane BL
J Cell Biochem Suppl; 1996; 25():197-204. PubMed ID: 9027619
[TBL] [Abstract][Full Text] [Related]
9. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
Bostwick DG; Aquilina JW
J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
[TBL] [Abstract][Full Text] [Related]
10. Nuclear cytometric changes in breast carcinogenesis.
Mommers EC; Poulin N; Sangulin J; Meijer CJ; Baak JP; van Diest PJ
J Pathol; 2001 Jan; 193(1):33-9. PubMed ID: 11169513
[TBL] [Abstract][Full Text] [Related]
11. Ploidy determination on histologic sections of breast cancer specimens by image analysis using mathematical correction algorithms.
Gschwendtner A; Mairinger T
Mod Pathol; 1997 Aug; 10(8):751-61. PubMed ID: 9267816
[TBL] [Abstract][Full Text] [Related]
12. Texture image analysis in differentiating malignant from benign adrenal cortical tumors in children and adults.
Shirata NK; Sredni ST; Castelo A; Santinelli A; Mendonça B; Montironi R; Filho AL; Zerbini MC
Anticancer Res; 2009 Aug; 29(8):3365-8. PubMed ID: 19661357
[TBL] [Abstract][Full Text] [Related]
13. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
14. Risk biomarkers and current strategies for cancer chemoprevention.
Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
[TBL] [Abstract][Full Text] [Related]
15. Quantitative study of ductal breast cancer progression: signatures of nuclei in proliferating breast lesions and in situ cancer.
Mariuzzi L; Mombello A; Rucco V; Morelli L; Zamò A; Thompson D; Vaught L; Bartels HG; Mariuzzi G; Bartels PH
Adv Clin Path; 2000 Apr; 4(2):87-97. PubMed ID: 11080789
[TBL] [Abstract][Full Text] [Related]
16. [Growth fraction (Ki67), ploidy balance and proliferation index in tumors of the urogenital tract and breast].
Charpin C; Habib MC; Piana L; Rampal M; Andrac L; Vacheret H; Martini P; Perez-Castillo M; Lavaut MN; Toga M
Ann Pathol; 1989; 9(5):331-9. PubMed ID: 2610776
[TBL] [Abstract][Full Text] [Related]
17. Image analysis versus flow cytometry for DNA ploidy quantitation of solid tumors: a comparison of six methods of sample preparation.
Danque PO; Chen HB; Patil J; Jagirdar J; Orsatti G; Paronetto F
Mod Pathol; 1993 May; 6(3):270-5. PubMed ID: 8346174
[TBL] [Abstract][Full Text] [Related]
18. Biomarker end-points in cancer chemoprevention trials.
Boone CW; Kelloff GJ
IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
[TBL] [Abstract][Full Text] [Related]
19. The flow cytometric analysis of premalignant and malignant lesions in head and neck squamous cell carcinoma.
Abou-Elhamd KE; Habib TN
Oral Oncol; 2007 Apr; 43(4):366-72. PubMed ID: 16931118
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
